Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Reaffirms Q1 Forecast

NEW YORK, April 8 - Visible Genetics today reaffirmed its first-quarter earnings projections, saying total revenue will come in between $4.2 million and $4.4 million.  

 

The company reported $3.6 million in revenue over the same period one year ago.

 

Visible Genetics said it will release on May 30 formal earnings results for the quarter ended March 31.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.